ArticleCancer research2020
ARRB1-Promoted NOTCH1 Degradation Is Suppressed by OncomiR miR-223 in T-cell Acute Lymphoblastic Leukemia.
Open access · greenAbstract read
In one paragraph
Article in Cancer research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 35 citations in OpenAlex.
- AutoML identification of microRNA biomarkers in high-risk pediatric acute lymphoblastic leukemia.Non-coding RNA research · 2025Article
- Review
- Identification of AK4 and RHOC as potential oncogenes addicted by adult T cell leukemia.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Notch Inhibitors and BH3 Mimetics in T-Cell Acute Lymphoblastic Leukemia.International journal of molecular sciences · 2024Review
- Multi-omics integration reveals potential stage-specific druggable targets in T-cell acute lymphoblastic leukemia.Genes & diseases · 2024Article
- Notch3-regulated microRNAs impair CXCR4-dependent maturation of thymocytes allowing maintenance and progression of T-ALL.Oncogene · 2024Article
- MiR-223-3p in Cancer Development and Cancer Drug Resistance: Same Coin, Different Faces.International journal of molecular sciences · 2024Review
- S1P-S1PR3-RAS promotes the progression of S1PR3Leukemia · 2023Article
- Review
- Niclosamide (NA) overcomes cisplatin resistance in human ovarian cancer.Genes & diseases · 2023Article
- Notch Partners in the Long Journey of T-ALL Pathogenesis.International journal of molecular sciences · 2023Review
- Dual roles of β-arrestin 1 in mediating cell metabolism and proliferation in gastric cancer.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- Modeling lung diseases using reversibly immortalized mouse pulmonary alveolar type 2 cells (imPAC2).Cell & bioscience · 2022Article
- MiR-652-5p elevated glycolysis level by targeting TIGAR in T-cell acute lymphoblastic leukemia.Cell death & disease · 2022Article
- MicroRNAs as Modulators of the Immune Response in T-Cell Acute Lymphoblastic Leukemia.International journal of molecular sciences · 2022Review
- A microRNA signature for clinical outcomes of pediatric ALL patients treated with TPOG protocols.American journal of cancer research · 2022Article
- LncRNA functional annotation with improved false discovery rate achieved by disease associations.Computational and structural biotechnology journal · 2022Article
- Identification of microRNA editing sites in three subtypes of leukemia.Frontiers in molecular biosciences · 2022Article
- Dysregulated Notch Signaling in the Airway Epithelium of Children with Wheeze.Journal of personalized medicine · 2021Article
- The many facets of miR-223 in cancer: Oncosuppressor, oncogenic driver, therapeutic target, and biomarker of response.Wiley interdisciplinary reviews. RNA · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors at 5 institutions in 4 countries.
Yi ShuCenter for Clinical Molecular Medicine, The Children's Hospital of Chongqing Medical University, Chongqing, China.
Yi WangCenter for Clinical Molecular Medicine, The Children's Hospital of Chongqing Medical University, Chongqing, China.
Wen-Qiong LvCenter for Clinical Molecular Medicine, The Children's Hospital of Chongqing Medical University, Chongqing, China.
Dan-Yi PengCenter for Clinical Molecular Medicine, The Children's Hospital of Chongqing Medical University, Chongqing, China.
Juan LiInstitute of Biochemistry and Cell Biochemistry, Shanghai Institute of Biomedical Sciences, Shanghai, China.
Hang ZhangCenter for Clinical Molecular Medicine, The Children's Hospital of Chongqing Medical University, Chongqing, China.
Guang-Jie JiangCenter for Clinical Molecular Medicine, The Children's Hospital of Chongqing Medical University, Chongqing, China.
Bi-Jie YangCenter for Clinical Molecular Medicine, The Children's Hospital of Chongqing Medical University, Chongqing, China.
Shan LiuCenter for Clinical Molecular Medicine, The Children's Hospital of Chongqing Medical University, Chongqing, China.
Jia ZhangCenter for Clinical Molecular Medicine, The Children's Hospital of Chongqing Medical University, Chongqing, China.
Yan-Hua ChenCenter for Clinical Molecular Medicine, The Children's Hospital of Chongqing Medical University, Chongqing, China.
Shi TangCenter for Clinical Molecular Medicine, The Children's Hospital of Chongqing Medical University, Chongqing, China.
Ke-Xing WanCenter for Clinical Molecular Medicine, The Children's Hospital of Chongqing Medical University, Chongqing, China.
Jun-Tao YuanCenter for Clinical Molecular Medicine, The Children's Hospital of Chongqing Medical University, Chongqing, China.
Wei GuoCenter for Clinical Molecular Medicine, The Children's Hospital of Chongqing Medical University, Chongqing, China.
Guo FuCenter for Clinical Molecular Medicine, The Children's Hospital of Chongqing Medical University, Chongqing, China.
Xin-Kun QiCenter for Clinical Molecular Medicine, The Children's Hospital of Chongqing Medical University, Chongqing, China.
Zhi-Dai LiuCenter for Clinical Molecular Medicine, The Children's Hospital of Chongqing Medical University, Chongqing, China.
Hai-Yan LiuMinistry of Education Key Laboratory of Child Development and Disorders, Chongqing, China.
Chao YangMinistry of Education Key Laboratory of Child Development and Disorders, Chongqing, China.
Ling-Huan ZhangMinistry of Education Key Laboratory of Child Development and Disorders, Chongqing, China.
Fang-Jie LiuCenter for Clinical Molecular Medicine, The Children's Hospital of Chongqing Medical University, Chongqing, China.
Jie YuMinistry of Education Key Laboratory of Child Development and Disorders, Chongqing, China.
Peng-Hui ZhangMinistry of Education Key Laboratory of Child Development and Disorders, Chongqing, China.
Bin QuDepartment of Biophysics, Center for Integrative Physiology and Molecular Medicine, School of Medicine, Saarland University, Homburg, Germany.
Hui ZhaoSchool of Biomedical Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China.
Tong-Chuan HeMolecular Oncology Laboratory, Departments of Surgery and Orthopaedic Surgery, The University of Chicago Medical Center, Chicago, Illinois. zoulin74@126.com tche@uchicago.edu.
Lin ZouCenter for Clinical Molecular Medicine, The Children's Hospital of Chongqing Medical University, Chongqing, China. zoulin74@126.com tche@uchicago.edu.
China International Science and Technology Cooperation · CNChinese University of Hong Kong · HKSaarland University · DEShanghai Cell Therapy Research Institute · CNUniversity of Chicago Medical Center · US
Funding
VIRAL ONCOLOGY CORE FACILITYP30CA014599 · NCI · UNIVERSITY OF CHICAGO · PI CHIEN-MIN KAO · 1985 to 2026
$122.1MRe-Engineering Translational Research at the University of ChicagoUL1TR000430 · NCATS · UNIVERSITY OF CHICAGO · PI SOLWAY, JULIAN · 2012 to 2016
$20.2MA genomewide discovery of chemoresistance-associated noncoding RNAs in human cancersR21CA226303 · NCI · UNIVERSITY OF CHICAGO · PI HE, TONG-CHUAN · 2018 to 2019
$381kNCATS NIH HHS UL1 TR000430NCI NIH HHS P30 CA014599NCI NIH HHS R21 CA226303
Abstract
T-cell acute lymphoblastic leukemia (T-ALL) is a type of aggressive leukemia with inferior prognosis. Although activating mutations of
Indexed as
3' Untranslated RegionsAdolescentAnimalsbeta-Arrestin 1Cell Line, TumorCell ProliferationChildChild, PreschoolFemaleGene Expression Regulation, LeukemicHumansMaleMiceMicroRNAsPrecursor T-Cell Lymphoblastic Leukemia-LymphomaProteolysis3' Untranslated RegionsARRB1 protein, humanbeta-Arrestin 1MicroRNAsMIR223, humanNOTCH1 protein, humanReceptor, Notch1Tumor Suppressor Proteins
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.